Research Analysts at Ladenburg Kept their “Buy” rating for Krystal Biotech (KRYS). The TP is Set to $50; Tucows (TCX) Has 1.15 Sentiment

Tucows Inc. (NASDAQ:TCX) Logo

Tucows Inc (TCX) investors sentiment decreased to 1.15 in Q4 2018. It’s down -0.19, from 1.34 in 2018Q3. The ratio has dropped, as 38 active investment managers increased or started new equity positions, while 33 sold and trimmed holdings in Tucows Inc. The active investment managers in our database now own: 6.15 million shares, up from 5.58 million shares in 2018Q3. Also, the number of active investment managers holding Tucows Inc in top ten equity positions increased from 3 to 4 for an increase of 1. Sold All: 12 Reduced: 21 Increased: 24 New Position: 14.

Ladenburg currently has a $50 TP on the $286.60M market cap company or 151.76% upside potential. In analysts report released on Wednesday morning, Krystal Biotech Inc (KRYS) stock had its “Buy” Rating maintained by stock analysts at Ladenburg.

Among 4 analysts covering Krystal Biotech (KRYS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Krystal Biotech has $57.5 highest and $32 lowest target. $41.17’s average target is 107.30% above currents $19.86 stock price. Krystal Biotech had 9 analyst reports since September 24, 2018 according to SRatingsIntel. The firm has “Buy” rating by Chardan Capital Markets given on Wednesday, March 6. H.C. Wainwright maintained Krystal Biotech, Inc. (NASDAQ:KRYS) rating on Wednesday, March 6. H.C. Wainwright has “Buy” rating and $32 target. The firm has “Buy” rating given on Monday, October 15 by H.C. Wainwright. Cantor Fitzgerald maintained the shares of KRYS in report on Tuesday, March 12 with “Buy” rating. As per Tuesday, March 12, the company rating was maintained by Chardan Capital Markets. The firm has “Buy” rating given on Wednesday, March 13 by H.C. Wainwright.

The stock decreased 5.65% or $1.19 during the last trading session, reaching $19.86. About 121,101 shares traded or 130.87% up from the average. Krystal Biotech, Inc. (KRYS) has risen 118.25% since March 14, 2018 and is uptrending. It has outperformed by 113.88% the S&P500. Some Historical KRYS News: 24/05/2018 – U.S. FDA Grants Fast Track Designation for Krystal Biotech’s KB103 for the Treatment of Dystrophic Epidermolysis Bullosa; 07/05/2018 – KRYSTAL BIOTECH – CASH AND CASH EQUIVALENTS TOTALED $47.2 MILLION AT MARCH 31, 2018, COMPARED WITH $49.6 MILLION AT DEC 31, 2017; 26/04/2018 – Krystal Biotech Announces FDA Clearance of IND on KB103 to Begin Enrolling Patients for the Treatment of Dystrophic Epidermolysis Bullosa; 26/04/2018 – KRYSTAL BIOTECH INC – INITIAL DATA FROM STUDY OF KB103 ARE EXPECTED TO BE RELEASED BY END OF 2018; 19/04/2018 – Krystal Biotech’s KB103 Receives Orphan Medicinal Product Designation in Europe for Dystrophic Epidermolysis Bullosa; 27/03/2018 Krystal Submits Investigational New Drug (IND) Application for KB103, Topical Gene Therapy Candidate for Dystrophic Epidermolysis Bullosa; 26/04/2018 – Krystal Biotech Announces FDA Clearance of IND on KB103 to Begin Enrolling Patients for the Treatment of Dystrophic Epidermolys; 09/05/2018 – Krystal Biotech Presents In Vivo KB103 Data at the International lnvestigative Dermatology Conference that Show Human COL7 lncorporating into Anchoring Fibrils with Proper Structural Orientation; 19/04/2018 – Krystal Biotech’s KB103 Receives Orphan Medicinal Product Designation in Europe for Dystrophic Epidermolysis Bullosa; 24/05/2018 – U.S. FDA Grants Fast Track Designation for Krystal Biotech’s KB103 for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company has market cap of $286.60 million. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease. It currently has negative earnings. It also engages in developing KB105, which is in preclinical studies to treat Lamellar Ichthyosis, which is an autosomal recessive disorder.

More notable recent Krystal Biotech, Inc. (NASDAQ:KRYS) news were published by: Nasdaq.com which released: “Krystal (KRYS) in Focus: Stock Moves 5.1% Higher – Nasdaq” on March 07, 2019, also Nasdaq.com with their article: “Krystal Strengthens Board of Directors with Appointment of Julian S. Gangolli – Nasdaq” published on March 04, 2019, Nasdaq.com published: “Krystal Biotech to Present at the Cowen and Company 39th Annual Health Care Conference – Nasdaq” on March 01, 2019. More interesting news about Krystal Biotech, Inc. (NASDAQ:KRYS) were released by: Seekingalpha.com and their article: “Krystal Biotech: Institutional Ownership Is Swelling – Seeking Alpha” published on February 22, 2019 as well as Seekingalpha.com‘s news article titled: “Krystal Biotech: Update And 2019 Outlook – Seeking Alpha” with publication date: December 20, 2018.

Since January 1, 0001, it had 0 buys, and 5 selling transactions for $1.12 million activity.

Tucows Inc. provides network access, domain name registration, email, mobile telephony, and other Internet services in the United States, Canada, and Germany. The company has market cap of $819.44 million. It operates in two divisions, Network Access Services and Domain Services. It has a 48.44 P/E ratio. The Network Access Services segment offers mobile and fixed high-speed Internet access services under the Ting brand, and Internet hosting and network consulting services.

More notable recent Tucows Inc. (NASDAQ:TCX) news were published by: Globenewswire.com which released: “Tucows Announces $40 Million Stock Buyback Program Nasdaq:TCX – GlobeNewswire” on February 13, 2019, also Seekingalpha.com with their article: “Tucows Inc 2018 Q4 – Results – Earnings Call Slides – Seeking Alpha” published on February 14, 2019, Fool.com published: “3 Things Tucows’ Management Wants You to Know – Motley Fool” on February 28, 2019. More interesting news about Tucows Inc. (NASDAQ:TCX) were released by: Fool.ca and their article: “Here’s Why You Should Expect a Mad March for Stocks – The Motley Fool Canada” published on February 27, 2019 as well as Nasdaq.com‘s news article titled: “Notable Friday Option Activity: CARA, CLVS, TCX – Nasdaq” with publication date: February 08, 2019.

Analysts await Tucows Inc. (NASDAQ:TCX) to report earnings on May, 8. They expect $0.30 EPS, down 14.29% or $0.05 from last year’s $0.35 per share. TCX’s profit will be $3.19M for 64.18 P/E if the $0.30 EPS becomes a reality. After $0.41 actual EPS reported by Tucows Inc. for the previous quarter, Wall Street now forecasts -26.83% negative EPS growth.

The stock increased 0.18% or $0.14 during the last trading session, reaching $77.02. About 26 shares traded. Tucows Inc. (TCX) has risen 29.80% since March 14, 2018 and is uptrending. It has outperformed by 25.43% the S&P500. Some Historical TCX News: 24/04/2018 – Tucows Short-Interest Ratio Rises 25% to 47 Days; 09/05/2018 – TUCOWS INC TC.TO – QTRLY BASIC NET EARNINGS PER COMMON SHARE $0.35; 15/05/2018 – Steamboat Capital Partners LLC Exits Position in Tucows; 09/05/2018 – TUCOWS INC TC.TO – QTRLY NET REVENUE $95.79 MLN VS $69.57 MLN; 09/05/2018 – Tucows 1Q Rev $95.8M; 16/03/2018 Tucows Closes Below 200-Day Moving Average: Technicals; 30/04/2018 – Ting Internet to bring gigabit fiber Internet to Fuquay-Varina, NC; 09/05/2018 – Tucows 1Q EPS 35c; 15/05/2018 – Caption Management Buys New 1% Position in Tucows; 23/04/2018 – Tucows Forms Golden Cross: Technicals

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.